Prospective longitudinal evaluation of men with initial prostate specific antigen levels of 4.0 ng./ml. or less

Journal of Urology

Volumn 157, Issue 5, 1997, Pages 1740-1743

  Harris, Clifford H ^a   Dalkin, Bruce L ^a   Martin, Elleen ^a   Marx, Phyllis C ^a   Ahmann, Frederick R ^a  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

prostate; prostate specific antigen; prostatic neoplasms

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANTIGEN DETECTION; ARTICLE; CANCER DIAGNOSIS; CANCER RISK; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER;

EID: 0030986966     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)64848-1     Document Type: Article

References (13)

1. Keetch, D. W., Catalona, W. J. and Smith, D. S.: Serial prostatic biopsies in men with persistently elevated serum prostate specific antigen values. J. Urol., 151: 1571, 1994.
2. Partin, A. W. and Oesterling, J. E.: The clinical usefulness of prostate specific antigen: update 1994. J. Urol., 152: 1358, 1994.
3. Stamey, T. A., Prestigiacomo, A. and Komatsu, K.: Physiological variation of serum prostate specific antigen (PSA) from a screening population in the range of 4-10 ng./ml. using the Hybritech Tandem-R PSA assay. J. Urol., part 2, 153: 420A, abstract 765, 1995.
4. Carter, H. B., Pearson, J. D., Waclawiw, Z., Metter, E. J., Chan, D. W., Guess, H. A. and Walsh, P. C.: Prostate-specific antigen variability in men without prostate cancer: effect of sampling interval on prostate-specific antigen velocity. Urology, 45: 591, 1995.
5. Oesterling, J. E., Suman, V. J., Zincke, H. and Bostwick, D. G.: PSA-detected (clinical stage T1c or B0) prostate cancer. Pathologically significant tumors. Urol. Clin. N. Amer., 20: 687, 1993.
6. Gann, P. H., Hennekens, C. H. and Stampfer, M. J.: A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. J.A.M.A., 273: 289, 1995.
7. Pickens, G. J. and Roehrborn, C. G.: Variability of repeated prostate specific antigen (PSA) measurements within less than 90 days in a well defined patient population. J. Urol., part 2, 153: 396A, abstract 671, 1995.
8. Riehmann, M., Rhodes, P. R., Cook, T. D., Grose, G. S. and Bruskewitz, R. C.: Analysis of variation in prostate-specific antigen values. Urology, 42: 390, 1993.
9. Cooner, W. H., Mosley, B. R., Rutherford, C. L., Jr., Beard, J. H., Pond, H. S., Terry, W. J. and Kidd, D. D.: Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen. J. Urol., 143: 1146, 1990.
10. Epstein, J. I., Walsh, P. C., Carmichael, M. and Brendler, C. B.: Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. J.A.M.A., 271: 368, 1994.
11. Terris, M. K., McNeal, J. E. and Stamey, T. A.: Detection of clinically significant prostate cancer by transrectal ultrasound-guided systematic biopsies. J. Urol., 148: 829, 1992.
12. Humphrey, P. A., Keetch, D. W., Smith, D. S., Shephard, D. L. and Catalona, W. J.: Prospective characterization of pathological features of prostatic carcinomas detected via serum prostate specific antigen based screening. J. Urol., 155: 816, 1996.
13. Colberg, J. W., Smith, D. S. and Catalona, W. J.: Prevalence and pathological extent of prostate cancer in men with prostate specific antigen levels of 2.9 to 4.0 ng./ml. J. Urol., 149: 507, 1993.